Efrat Luttwak, MD, MPH

Attending Physician and Clinical Investigator

Efrat Luttwak, MD, MPH

Attending Physician and Clinical Investigator
Share
Share

I am a clinical investigator and attending physician on the lymphoma service. I graduated cum laude from the Jerusalem Hebrew University at Hadassah Medical Center, also earning an MPH in epidemiology with honors. My medical career at Tel Aviv-Sourasky Medical Center included positions from internal medicine resident to hematology fellow and attending physician. I recently completed advanced oncology fellowship training at Memorial Sloan Kettering Cancer Center under the mentorship of Dr. Salles. My research focuses on clinical trials and translational research in lymphoma, particularly CAR-T cell therapy. I aim to stratify patients better, identify early failures in CAR-T cell therapy, and intervene early, conducting basic and clinical patient-oriented research with the potential for significant clinical impact.

Awards

  • Parasol Scholarship (2018)
  • The Rosenblatt Foundation Scholarship (2022)
  • ASH Abstract Achievement Award (2023)

Publications

Luttwak E, Hagin D, Perry C, Wolach O, Itchaki G, Amit O, et al. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. Bone Marrow Transplantation. 2021;56(5).

Cohen YC, Zada M, Wang SY, Bornstein C, David E, Luttwak E, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature Medicine. 2021;27(3).

Cohen, D., Luttwak, E., Beyar-Katz, O., Hazut Krauthammer, S., Bar-On, Y., Amit, O., Gold, R., Perry, C., Avivi, I., Ram, R., & Even-Sapir, E. (2021). [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-021-05551-5, 2022

Avivi I, Perry C, Segman Y, Luttwak E, Herishanu Y, et al. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. PMID: 35083525.

Beyar Katz, O., C. Perry…Luttwak E, B. Avni, T. Zuckerman, et al. “Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to Anti-Cd19-Car T Cells: A Real Word Retrospective Multicenter Study.” [In eng]. Eur J Haematol 111, no. 1 (Jul 2023): 63-71. https://doi.org/10.1111/ejh.13968.